


INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known			
		Application Number	10/635,807		
		Filing Date	August 5, 2003		
		First Named Inventor	RUBENSTEIN, EDWARD, et. al.		
		Art Unit	Unassigned		
		Examiner Name	Unassigned		
Page	3	of		Attorney Docket Number	018050-000140US

U.S. PATENT DOCUMENTS					
Examiner	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number Kind Code ² (if known)			
JLB	A	3,654,932	04/1972	Newkirk et al.	
	B	3,864,259	02/1975	Newhart	
	C	3,886,948	06/03/75	Hakim	
	D	4,156,422	05/29/79	Hildebrandt et al.	
	E	4,261,341	04//1981	Hakim et al.	
	F	4,375,816	03/08/83	Labianca	
	G	4,560,375	12/24/85	Schulte et al.	
	H	4,598,579	07/08/86	Cummings et al.	
	I	4,605,395	08/12/86	Rose et al.	
	J	4,610,658	09/1986	Buchwald et al.	
	K	4,673,384	06/16/87	Marion	
	L	4,675,003	06/1987	Hooven	
	M	4,681,559	07/1987	Hooven	
	N	4,713,065	12/1987	Koot	
	O	4,933,156	06/12/90	Quay et al.	
	P	4,950,232	08/21/90	Ruzicka et al.	
	Q	5,039,511	08/13/91	Quay	
	R	5,069,663	12/1991	Sussman	
	S	5,167,615	12/1992	East et al.	
	T	5,334,315	08/02/94	Matkovich et al.	
	U	5,336,166	08/09/94	Sierra	
	V	5,368,556	11/1994	Lecuyer	
	W	5,385,541	01/31/95	Kirsch et al.	
	X	5,387,188	02/07/95	Watson	

Examiner Signature	<i>Se Branaul</i>	Date Considered	11-14-04
--------------------	-------------------	-----------------	----------

¹ EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Page 5

of

Complete If Known

Application Number	10/635,807
Filing Date	August 5, 2003
First Named Inventor	RUBENSTEIN, EDWARD, et. al.
Art Unit	Unassigned
Examiner Name	Unassigned
Attorney Docket Number	018050-000140US

FOREIGN PATENT DOCUMENTS

Examiner Initials ¹	Cite No. ¹	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ²
		Country Code ³	Number ⁴	Kind Code ⁵ (if known)				

NON PATENT LITERATURE DOCUMENTS

Examiner Initials ¹	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
RB	AG	Adams et al., "Disturbances of cerebrospinal fluid circulation, including hydrocephalus and meningeal reactions," <i>Principles of Neurology</i> , Fourth Edition, Chapter 30, 1989, pp. 501-502.	
	AH	Adams, R.D. et al., "Symptomatic occult hydrocephalus with 'normal' cerebrospinal-fluid pressure" <i>The New England Journal of Medicine</i> , Vol. 273, No. 3, pages 117-126 (July 15, 1965).	
	AI	Appenzeller, Otto & Salmon, James H., "Treatment of parenchymatous degeneration of the brain by ventriculo-atrial shunting of the cerebrospinal fluid," <i>Journal of Neurosurgery</i> , Volume XXVI, pages 478-482, (January-June 1967).	
	AJ	Arai et al., "Tau in cerebrospinal fluid: a potential diagnostic marker," <i>Ann. Neurology</i> , vol. 38, 1995, pp. 649-652.	
	AK	Bannister, Roger, et al., "Isotope encephalography in the diagnosis of dementia due to communicating hydrocephalus" <i>The Lancet</i> , pgs. 1014-1017, (November 11, 1967).	
	AL	Barnett et al., "Normal pressure hydrocephalus in children and young adults" <i>Neurosurgery</i> (1987) 20(6):904-907.	
	AM	Boon et al., "Does CSF outflow resistance predict the response to shunting in patients with normal pressure hydrocephalus?" <i>Acta Neurochir.</i> (1998) 71:331-333.	
	AN	Boon et al., "Dutch normal-pressure hydrocephalus study: Prediction of outcome after shunting by resistance to outflow of cerebrospinal fluid" <i>J. Neurosurg.</i> (1997) 87:687-693.	
RB	AO	Bush et al., "Beta A-4 amyloid protein and its precursor in Alzheimer's disease," <i>Pharmac. Tera.</i> , Vol. 56, 1992, pp. 97-117.	

Examiner
Signature

[Signature]


Date
Considered

11-14-02

¹ EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

² Applicant's unique citation designation number (optional). ³ Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.88. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449/PTO		Complete If Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Applicant Number	10/635,807
		Filing Date	August 5, 2003
		First Named Inventor	RUBENSTEIN, EDWARD, et. al.
		Art Unit	Unassigned
		Examiner Name	Unassigned
Page 6 of	Attorney Docket Number	018050-000140US	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Country Code ³	Number ⁴ Kind Code ⁵ (if known)			
SLB	AP		Chen, I.H. et al., "Effectiveness of shunting in patients with normal pressure hydrocephalus predicted by temporary, controlled-resistance, continuous lumbar drainage: a pilot study," <i>Journal of Neurology, Neurosurgery, and Psychiatry</i> , 1994, S/1430-1432.			1
	AQ		Clarfield, "Normal-pressure hydrocephalus: Saga or swamp?" <i>JAMA</i> (1989) 262(18):2592-2593.			
	AR		Damasceno et al., "The predictive value of cerebrospinal fluid tap-test in normal pressure hydrocephalus" <i>Arg. Neurosiquiatr.</i> (1997) 55(2):179-185.			
	AS		Friedland, "Normal-pressure hydrocephalus and the saga of the treatable dementias" <i>JAMA</i> (1989) 262(18):2577-2581.			
	AT		Golomb et al., "Alzheimer's disease comorbidity in normal pressure hydrocephalus: prevalence and shunt response" <i>J. Neurol. Neurosurg. Psych.</i> (2000) 68:778-781.			
	AU		Graff-Radford et al., "Normal-pressure hydrocephalus" <i>Neurol.</i> (1986) 43:940-942.			
	AV		Gustafson et al., "Recovery in hydrocephalic dementia after shunt operation" <i>J. Neurol. Neurosurg. Psych.</i> (1978) 41:940-947.			
	AW		Hakim et al., "The special clinical problem of symptomatic hydrocephalus with normal cerebrospinal fluid pressure. Observations on cerebrospinal fluid hydrodynamics" <i>J. Neurol. Sci.</i> (1965) 2:307-327.			
	AX		Holodny et al., "Focal dilation and paradoxical collapse of cortical fissures and sulci in patients with normal-pressure hydrocephalus" <i>J. Neurosurg.</i> (1998) 89:742-747.			
	AY		Kaye et al., "Plasticity in the aging brain" <i>Arch Neurol.</i> (1990) 47:1336-1341.			
	AZ		Ko et al., "Cerebrospinal fluid control system" <i>Proceedings of the IEEE</i> , Vol. 76, No. 9, pp. 1226-1235, September 1988.			
SLB	BA		Martinez et al., "Relationship of interleukin-1 beta and beta ₂ -microglobulin with neuropeptides in cerebrospinal fluid of patients with dementia of the Alzheimer type," <i>J. Neuroimmunology</i> , Vol. 48, 1993, pp 235-240.			

Examiner Signature	<i>SLB Jones</i>	Date Considered	11-14-04
--------------------	------------------	-----------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.
60026962 v1

PTO/SB/08B (04-03)
Approved for use through 04/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449/PTO		<div style="text-align: center;"> Complete if Known </div>	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Applicant Number	10/635,807
		Filing Date	August 5, 2003
		First Named Inventor	RUBENSTEIN, EDWARD, et. al.
		Art Unit	Unassigned
		Examiner Name	Unassigned
Page	7	of	
		Attorney Docket Number	018050-000140US

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. ¹	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³	Number ⁴ <small>(Kind Code⁵ if known)</small>				
BB			Mataró et al., "Cognitive changes after cerebrospinal fluid shunting in young adults with spina bifida and assumed arrested hydrocephalus" <i>J. Neurol. Neurosurg. Psych.</i> (2000) 68:615-621.				
BC			Mogilner et al., "Hydrocephalus: Does coexistent Alzheimer's disease affect outcome?" <i>Poster Presentation from AANS 1999 New Orleans</i> , http://cnshome.org/abstrats , 2 pages total.				
BD			Nakamura et al., "Amyloid beta protein levels in cerebrospinal fluid are elevated in early-onset Alzheimer's disease," <i>Ann. Neurology</i> , Vol. 36, 1994, pp. 903-911.				
BE			Ono et al., "Formation of amyloid-like substance from beta-2-microglobulin in vitro. Role of serum amyloid P component: a preliminary study," <i>Nephron</i> , Vol. 66, 1994, pp. 404-407.				
BF			Salmon, James H., "Senile and presenile dementia" <i>Geriatrics</i> (December 1969) 24 (12) : 67-72.				
BG			Shenkin et al., "Ventricular shunting for relief of senile symptoms" <i>JAMA</i> (1973) 225(12):1486-1489.				
BH			Skinhøj, Erik, "Determination of regional cerebral bloodflow in man" Head injury conference proceedings, held at the University of Chicago Center for Continuing Education with Joseph P. Evans as host. No. 34, pgs. 431-438.				
BI			Vanneste et al., "Shunting normal-pressure hydrocephalus: Do the benefits outweigh the risks?" <i>Neurol.</i> (1992) 42:54-59.				
BJ			Vorstrup et al., "Cerebral blood flow in patients with normal-pressure hydrocephalus before and after shunting" <i>J. Neurol.</i> (1987) 66:379-387.				
BK			Williams et al., "Evaluation of shunt function in patients who are never better, or better than worse after shunt surgery for NPH" <i>Acta Neurochir.</i> (1998) 71:368-370.				
BL			Williams et al., "Comparison of Pcsf monitoring and controlled CSF drainage diagnose normal pressure hydrocephalus" <i>Acta Neurochir.</i> (1998) 71:328-330.				

Examiner Signature	<i>Altoramp</i>	Date Considered	11-14-04
-----------------------	-----------------	--------------------	----------

EXAMINER: Initial If reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.
 This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

60026962 v1 If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

